MétaCan
Menu
← Back to cohort
Record W2912533412 · doi:10.1136/bmjopen-2018-024222

Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials

2019· review· en· W2912533412 on OpenAlexaff
Shomron Ben‐Horin, Yue Zhao, Jing Guo, Ren Mao, Lena Novack, Ruslan Sergienko, Jian Zhang, Taku Kobayashi, Toshifumi Hibi∥, Yehuda Chowers, Jean‐Frédéric Colombel, Laurent Peyrin‐Biroulet, Gilaad G. Kaplan, Minhu Chen

Bibliographic record

VenueBMJ Open · 2019
Typereview
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsUniversity of Calgary
Fundersnot available
KeywordsMedicineMeta-analysisProtocol (science)Inflammatory bowel diseaseDuration (music)Randomized controlled trialDiseaseInternal medicineClinical trialPhysical therapySystematic reviewAlternative medicineMEDLINEIntensive care medicinePathology

Abstract

fetched live from OpenAlex

INTRODUCTION: Crohn's disease (CD) and ulcerative colitis (UC) are remitting-relapsing inflammatory diseases often culminating in disease complications and/or need for surgery. Biologic monoclonal antibody drugs ('Biologics') are efficacious for both diseases, but there are no systematic assessments of their efficacy if administered early after disease onset ('top-down' strategy) vis-à-vis later in the course of disease ('step-up' approach). METHODS AND ANALYSIS: Electronic databases (MEDLINE, EMBASE/EMBASE classic Cochrane CENTRAL register of controlled trials, the Cochrane IBD Group Specialised Trials Register and Clinicaltrials.gov registry) will be searched to identify all randomised placebo-controlled clinical trials of food and drug administration (FDA)-approved biologics for CD and UC (by March 2016). Two independent reviewers will screen identified papers, extract data and assess the risk of bias according to the Cochrane Handbook for Systematic Reviews of Interventions. Individual-patient-level data (IPD) will be extracted from the identified trials through data-sharing platforms for pharmaceutical companies' sponsored trials and by contacting principal investigators of independent investigator-initiated trials. We will analyse induction of remission in patients with early-disease (<18 months since disease onset) versus patients with longer disease duration, using a generalised linear mixed effect model and by a two-stage approach using coefficient for the treatment-by-subgroup interaction within each trial. We will perform receiver operator curve analysis of optimal disease duration for response. Analyses will be separate for CD and UC. This first-of-its-kind meta-analysis at IPD level of interaction of disease duration with the response to biologics in UC and CD may elucidate the impact of early initiation of biologics, which is of paramount importance for clinical practice and management strategies of inflammatory bowel disease. ETHICS AND DISSEMINATION: This meta-analysis was approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University. Findings will be published in peer-reviewed journal and disseminated via scientific meetings and links with organisations. PROSPERO REGISTRATION NUMBER: CRD42018041961.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.097
metaresearch head score (Gemma)0.147
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.097
Threshold uncertainty score0.512

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0970.147
Meta-epidemiology (narrow)0.0090.006
Meta-epidemiology (broad)0.0320.036
Bibliometrics0.0150.014
Science and technology studies0.0030.005
Scholarly communication0.0090.008
Open science0.0070.005
Research integrity0.0090.008
Insufficient payload (model declined to judge)0.0490.007

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.319
GPT teacher head0.489
Teacher spread0.170 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueBMJ Open→Same topicInflammatory Bowel Disease→French-language works237,207→